The latest price target for Charles River (NYSE:CRL) was reported by UBS on February 25, 2026. The analyst firm set a price target for $175.00 expecting CRL to rise to within 12 months (a possible 13.93% upside). 30 analyst firms have reported ratings in the last year.

The latest analyst rating for Charles River (NYSE:CRL) was provided by UBS, and Charles River maintained their neutral rating.

The last upgrade for Charles River Laboratories International Inc happened on November 6, 2025 when Baird raised their price target to $199. Baird previously had a neutral for Charles River Laboratories International Inc.

The last downgrade for Charles River Laboratories International Inc happened on March 21, 2025 when Goldman Sachs changed their price target from $190 to $170 for Charles River Laboratories International Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Charles River, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Charles River was filed on February 25, 2026 so you should expect the next rating to be made available sometime around February 25, 2027.

While ratings are subjective and will change, the latest Charles River (CRL) rating was a maintained with a price target of $170.00 to $175.00. The current price Charles River (CRL) is trading at is $153.60, which is out of the analyst’s predicted range.